(VIANEWS) – FRØY (FROY.OL), ITERA (ITERA.OL), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. FRØY (FROY.OL)
14% sales growth and 6.9% return on equity
Frøy ASA provides integrated service to the aquaculture industry in Norway. The company offers wellboat services, sea freight, de-lice and treatment, mooring and laying, ring washing and cage services, net washing and mending, inspection and certification, bottom mapping and documentation, slep, diving and ROV, and control system. It owns and operates 18 wellboats, 60 aqua service vessels, 3 feed transport vessels, and 13 local offices along the Norwegian coast. The company was founded in 2019 and is headquartered in Sistranda, Norway.
Earnings Per Share
As for profitability, FRØY has a trailing twelve months EPS of kr2.63.
PE Ratio
FRØY has a trailing twelve months price to earnings ratio of 25.4. Meaning, the purchaser of the share is investing kr25.4 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.9%.
More news about FRØY.
2. ITERA (ITERA.OL)
11.2% sales growth and 138.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.73.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 19.04. Meaning, the purchaser of the share is investing kr19.04 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 138.07%.
Sales Growth
ITERA’s sales growth is 21% for the current quarter and 11.2% for the next.
Volume
Today’s last reported volume for ITERA is 167 which is 99.23% below its average volume of 21755.
More news about ITERA.
3. NAVAMEDIC (NAVA.OL)
9.6% sales growth and 16.31% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr0.45.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 85.56. Meaning, the purchaser of the share is investing kr85.56 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.31%.
Moving Average
NAVAMEDIC’s value is below its 50-day moving average of kr38.64 and way above its 200-day moving average of kr34.23.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr38.50 at 02:20 EST, way under its 52-week high of kr43.60 and way above its 52-week low of kr25.00.
Sales Growth
NAVAMEDIC’s sales growth is 72.2% for the ongoing quarter and 9.6% for the next.
More news about NAVAMEDIC.
4. ORKLA (ORK.OL)
7.4% sales growth and 12.77% return on equity
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr5.04.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 15.09. Meaning, the purchaser of the share is investing kr15.09 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.77%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
ORKLA’s EBITDA is 34.14.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 12.9% and a negative 12%, respectively.
Sales Growth
ORKLA’s sales growth is 17.4% for the ongoing quarter and 7.4% for the next.
Yearly Top and Bottom Value
ORKLA’s stock is valued at kr76.06 at 02:20 EST, way under its 52-week high of kr85.20 and way higher than its 52-week low of kr67.06.
More news about ORKLA.
